Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: PRnewswire
- Lawsuit Background: A securities class action lawsuit has been filed against Gossamer Bio, Inc. following its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025 to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and exacerbating investor concerns about the company's future prospects, which may lead to a long-term decline in investor confidence.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, suggesting significant deficiencies in the company's transparency that affected investor decision-making.
- Listing Risk: Gossamer revealed on April 9, 2026, that it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks, further impacting its financing capabilities and market reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.390
Low
10.00
Averages
12.33
High
15.00
Current: 0.390
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure
- Lawsuit Background: A securities class action lawsuit has been filed against Gossamer Bio, Inc. following its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025 to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and exacerbating investor concerns about the company's future prospects, which may lead to a long-term decline in investor confidence.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, suggesting significant deficiencies in the company's transparency that affected investor decision-making.
- Listing Risk: Gossamer revealed on April 9, 2026, that it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks, further impacting its financing capabilities and market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, leading to artificially inflated stock prices and causing investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating the firm's commitment to safeguarding investor rights and laying the groundwork for future legal actions.
- Legal Fee Structure: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover losses, which reduces legal risks for investors and enhances the appeal of participating in the lawsuit.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by June 1, 2026.
- Clinical Trial Failure: On February 23, 2026, Gossamer reported that its PROSERA study for seralutinib in treating pulmonary arterial hypertension failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence in the company's future.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, particularly in securities and antitrust cases, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling such complex legal matters.
See More
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure
- Lawsuit Background: A securities class action lawsuit has been filed against Gossamer Bio, Inc. following its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025 to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and exacerbating investor concerns about the company's future prospects, which may lead to a long-term decline in investor confidence.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, suggesting significant deficiencies in the company's transparency that affected investor decision-making.
- Listing Risk: Gossamer revealed on April 9, 2026, that it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks, further impacting its financing capabilities and market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, leading to artificially inflated stock prices and causing investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating the firm's commitment to safeguarding investor rights and laying the groundwork for future legal actions.
- Legal Fee Structure: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover losses, which reduces legal risks for investors and enhances the appeal of participating in the lawsuit.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by June 1, 2026.
- Clinical Trial Failure: On February 23, 2026, Gossamer reported that its PROSERA study for seralutinib in treating pulmonary arterial hypertension failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence in the company's future.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, particularly in securities and antitrust cases, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling such complex legal matters.
See More
